Investor

  • $50Bn+ Global market opportunity
  • Proven concept. Pre-Clinical work completed at PHE, Porton Down
  • New Vaccine development and production in minimal timeframe
  • Only 100 litres of virus culture estimated per 100m people, opposed to 10 million litres
  • Safer – negligible side effects or reactions
  • Greater efficacy
  • Overcomes the needle phobia of > 700 million people worldwide
  • Level up developing and LMI Countries